My Heart is Broken - But I'm Determined

-

 
My heart is broken. Dave Bjork, Cancer Research Evangelist has had a tough week. My friend Stephen Muir passed away yesterday. He was 45 years old, never smoked, but died of stage 4 non-small cell lung cancer. Wow. Diagnosed August 8th, died September 4th.  Wow.
I’ve been gearing up for a major fundraising effort this fall to support the research of Dr. Daniel Haber, the Director of the Massachusetts General Hospital Cancer Center. The sad irony is that my friend Stephen’s story is so profoundly relevant to the research I am supporting. I feel like there is a reason and a purpose for my friendship with Stephen to make a difference in the work that I do at the National Foundation for Cancer Research.

Tumors change over time, often developing resistance to treatment. To remain effective, targeted therapies need to address these tumor changes as they occur. That requires constant monitoring of tumors, so that doctors can make appropriate adjustments to patients’ treatment plans.  My friend had the EGFR mutation, and there is a targeted therapy to treat this mutation, Tarceva.  But it was too late for him. And so much work remains to get to the point where we can diagnose cancer with a blood biopsy.  This is the whole point of Dr. Haber’sresearch.  We need to get to the place where we can go for an annual physical and through a simple blood draw determine if we have cancer. Or patients like me, can find out if our cancer has come back.

But we need to do the research first to get to that place where it’s really a diagnostic blood biopsy. I’m supporting a research project that will make a difference. Thanks to a new and exciting technology, it is now increasingly possible to collect genetic material from tumors—even whole tumor cells—during a routine blood draw, or a liquid biopsy. NFCR-supported scientist Daniel Haber
and his colleagues at Massachusetts General Hospital have developed a new technology that allows clinicians to monitor tumor mutations as they occur, so that treatments can be altered to address those changes in tumor biology. The technology has the potential to radically change the way cancer is treated.

Dr. Haber and colleagues developed a credit-card-sized device, called CTC-iChip, that can be used to isolate minute CTCs collected via liquid biopsy and keep them viable to analyze their drug sensitivity. Testing CTCs derived from liquid biopsies could provide a rapid, noninvasive way to guide targeted therapy for individual patients. If a tumor acquires resistance to a first-line treatment, this drug-based monitoring may help to identify appropriate second-line therapy, better enabling that one-two punch that cancer treatment can require.

In the next phase of the research, Dr. Haber’s team will develop technology to enable culturing CTCs collected from blood samples from patients with metastatic lung cancer. Lung cancer is the No. 1 killer for both men and women in the United States, causing nearly 30% of all cancer deaths each year. CTCs, which are representative of multiple tumor lesions in patients, can be sampled repeatedly over the course of a patient’s treatment, with minimally invasive blood draws. The CTCs can be analyzed in the laboratory, both to watch for changes that may occur and to evaluate the effectiveness of different drugs or drug combinations. This step prevents the need to test drug regimens directly in humans.

Culturing CTCs from patients with lung cancer will likely generate a far more refined picture of tumor composition than past technologies have produced. In addition, focusing on genetically directed treatments will help researchers identify potential mechanisms of disease resistance and effective drug combinations. Results of this laboratory research would lay the groundwork for better designed clinical trials and eventually better targeted treatments.

The technology of liquid biopsy is poised on the cusp of truly enabling personalized medicine – not just for patients with lung cancer, but for patients with a wide variety of cancer types – without the need for painful, repeated biopsies. So, in honor of my friend Stephen Muir, I persevere and support amazing scientists like Daniel Haber.

Popular posts from this blog

A Bowl of Gratitude

-
Image
I was introduced recently to Lynne Sarnoff-Christensen by her cousin, and my friend Jeffrey Cohen. You see, she makes pottery and well, more specifically she make “bowls of gratitude”. So of course, Jeffrey knew that I would hit it off with Lynne because he knows I live a life full of gratitude. Another friend, Keith Spiro said I just had to buy a bowl – so I did. The idea is to put notes in the bowl about things you are grateful for. So it’s my new thing. I’ve long been a fan of Shawn Achor and I’ve gotten into the habit of writing down things that I am grateful for. So this bowl of gratitude will be where I put my notes. And I will encourage my family to also add their notes to the bowl. We have a tradition on Thanksgiving to go around the table before we dig in to our meal, to share what we are thankful for. We shouldn’t just do this at Thanksgiving! When I called Lynne, she explained her philosophy and I get it: “You didn’t get from there to here without people believ...
Read more

The Power of Community: The White Ribbon Project

-
Image
The Greek meaning of evangelist is "bringing the good news." It's why I call my podcast the Research Evangelist Podcast. I love to share stories about people in life sciences who are doing amazing work to advance cancer research. And it's why The White Ribbon Project has captured my attention. The White Ribbon Project is a grassroots movement of lung cancer patients, advocates, clinicians, researchers friends and families with a mission to change the public perception of lung cancer by spreading awareness that anyone with lungs can get lung cancer. No one deserves lung cancer whether you smoked or not. But lung cancer is not just a smokers disease, as more and more people are getting lung cancer with no smoking history. The White Ribbon Project is proving that the power of a community that cares can be unleashed by individuals who wanted to make a difference - people that didn't set out to start a movement. It's because their story is so sincere and authentic...
Read more

Time to Move Beyond the Ribbons?

-
This past week, I had the pleasure of meeting Massachusetts Senator Ed Markey and Harvard Medical School Professor of Genetics, Dr. Fred Alt. They were both in Washington, DC for the presentation of the 2015 NFCR Szent-Györgyi Prize for Progress in Cancer Research, which was awarded to Dr. Alt and keynoted by Sen. Markey.   The common theme I heard from both of these distinguished leaders was captured in a Huffington Post article written by Sam Stein , who attended the event . Stein succinctly wrote that “U.S. Science has never been more imperiled”. He noted that the lack of funding for basic scientific research not only prevents new discoveries, but it also means that we are losing promising scientists whose work can’t get funded.    10 years ago, nearly a third of qualified research was funded by NIH.   Now that number is only 14% (actually even lower for oncology, near 9%).   As Sen. Markey said, “sadly, support for scientific research in our countr...
Read more